The Cooperative roles of inflammation and oxidative stress in the pathogenesis of hypertension

Antioxidants and Redox Signaling

Volumn 20, Issue 1, 2014, Pages 102-120

  Crowley, Steven D ^a  

^a DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AUTOANTIBODY; CYCLOPHILIN A; REACTIVE OXYGEN METABOLITE;

ADAPTIVE IMMUNITY; ATHEROGENESIS; BLOOD PRESSURE VARIABILITY; BLOOD VESSEL FUNCTION; CARDIOVASCULAR INFLAMMATION; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM FUNCTION; HUMAN; HYPERTENSION; IMMUNE RESPONSE; INFLAMMATORY CELL; KIDNEY FUNCTION; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM; VASCULARIZATION; VASCULITIS;

ANIMALS; CARDIOVASCULAR SYSTEM; HUMANS; HYPERTENSION; INFLAMMATION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84880924241     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5258     Document Type: Review

References (202)

1. Abdullah HI, Pedraza PL, McGiff JC, and Ferreri NR. CaR activation increases TNF production by mTAL cells via a Gi-dependent mechanism. Am J Physiol Renal Physiol 294: F345-F354, 2008.
2. Almasan A and Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14: 337-348, 2003.
3. Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, and Atar D. Tumor necrosis factor-{alpha} antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 55: 333-338, 2010.
4. Arai T, Kelly SA, Brengman ML, Takano M, Smith EH, Goldschmidt-Clermont PJ, and Bulkley GB. Ambient but not incremental oxidant generation effects intercellular adhesion molecule 1 induction by tumour necrosis factor alpha in endothelium. Biochem J 331 (Pt 3): 853-861, 1998.
5. Bakker EN, Matlung HL, Bonta P, de Vries CJ, van Rooijen N, and Vanbavel E. Blood flow-dependent arterial remodelling is facilitated by inflammation but directed by vascular tone. Cardiovasc Res 78: 341-348, 2008.
6. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, and Schiffrin EL. T Regulatory lymphocytes prevent angiotensin ii-induced hypertension and vascular injury. Hypertension 57: 469-476, 2011.
7. Bataillard A, Freiche JC, Vincent M, Sassard J, and Touraine JL. Antihypertensive effect of neonatal thymectomy in the genetically hypertensive LH rat. Thymus 8: 321-330, 1986.
8. Battula S, Hao S, Pedraza PL, Stier CT, and Ferreri NR. Tumor necrosis factor-A is an endogenous inhibitor of Na+ -K + -2Cl -cotransporter (NKCC2) isoform A in the thick ascending limb. Am J Physiol Renal Physiol 301: F94-F100, 2011.
9. Baylis C, Mitruka B, and Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90: 278-281, 1992.
10. Behrendt D and Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol 90: 40L-48L, 2002.
11. Bertani T, Abbate M, Zoja C, Corna D, Perico N, Ghezzi P, and Remuzzi G. Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol 134: 419-430, 1989.
12. Bjorkbacka H. Multiple roles of Toll-like receptor signaling in atherosclerosis. Curr Opin Lipidol 17: 527-533, 2006.
13. Boesen EI, Sasser JM, Saleh MA, Potter WA, Woods M, Warner TD, Pollock JS, and Pollock DM. Interleukin-1beta, but not interleukin-6, enhances renal and systemic endothelin production in vivo. Am J Physiol Renal Physiol 295: F446-F453, 2008.
14. Bustamante J, Arias AA, Vogt G, Picard C, Galicia LB, Prando C, Grant AV, Marchal CC, Hubeau M, Chapgier A, de Beaucoudrey L, Puel A, Feinberg J, Valinetz E, Janniere L, Besse C, Boland A, Brisseau JM, Blanche S, Lortholary O, Fieschi C, Emile JF, Boisson-Dupuis S, Al-Muhsen S, Woda B, Newburger PE, Condino-Neto A, Dinauer MC, Abel L, and Casanova JL. Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat Immunol 12: 213-221, 2011.
15. Caligiuri G, Paulsson G, Nicoletti A, Maseri A, and Hansson GK. Evidence for antigen-driven T-cell response in unstable angina. Circulation 102: 1114-1119, 2000.
16. Callera GE, Montezano AC, Yogi A, Tostes RC, He Y, Schiffrin EL, and Touyz RM. c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 46: 1032-1038, 2005.
17. Calo LA, Zaghetto F, Pagnin E, Davis PA, De Mozzi P, Sartorato P, Martire G, Fiore C, and Armanini D. Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes. J Clin Endocrinol Metab 89: 1973-1976, 2004.
18. Cardinale JP, Sriramula S, Mariappan N, Agarwal D, and Francis J. Angiotensin II-induced hypertension is modulated by nuclear factor-kappaBin the paraventricular nucleus. Hypertension 59: 113-121, 2012.
19. Castier Y, Brandes RP, Leseche G, Tedgui A, and Lehoux S. p47phox-dependent NADPH oxidase regulates flowinduced vascular remodeling. Circ Res 97: 533-540, 2005.
20. Chae CU, Lee RT, Rifai N, and Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 38: 399-403, 2001.
21. Chao J, Li HJ, Yao YY, Shen B, Gao L, Bledsoe G, and Chao L. Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogenactivated protein kinase activity. Hypertension 49: 490-497, 2007.
22. Chen CC, Pedraza PL, Hao S, Stier CT, and Ferreri NR. TNFR1-deficient mice display altered blood pressure and renal responses to ANG II infusion. Am J Physiol Renal Physiol 299: F1141-F1150, 2010.
23. Chen XL, Tummala PE, Olbrych MT, Alexander RW, and Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 83: 952-959, 1998.
24. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, and Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am J Hypertens 17: 568-573, 2004.
25. Cooper AL and Beasley D. Hypoxia stimulates proliferation and interleukin-1alpha production in human vascular smooth muscle cells. Am J Physiol 277: H1326-H1337, 1999.
26. Cooper D, Stokes KY, Tailor A, and Granger DN. Oxidative stress promotes blood cell-endothelial cell interactions in the microcirculation. Cardiovasc Toxicol 2: 165-180, 2002.
27. Cowley AW, Jr., Mori T, Mattson D, and Zou AP. Role of renal NO production in the regulation of medullary blood flow. Am J Physiol Regul Integr Comp Physiol 284: R1355-R1369, 2003.
28. Criss WE and McKerns KW. Inhibitors of the catalytic activity of bovine adrenal glucose-6-phosphate dehydrogenase. Biochim Biophys Acta 184: 486-494, 1969.
29. Crowley SD, Frey CW, Gould SK, Griffiths R, Ruiz P, Burchette JL, Howell DN, Makhanova N, Yan M, Kim HS, Tharaux PL, and Coffman TM. Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol 295: F515-F524, 2008.
30. Crowley SD, Song YS, Lin EE, Griffiths R, Kim HS, and Ruiz P. Lymphocyte responses exacerbate angiotensin IIdependent hypertension. Am J Physiol Regul Integr Comp Physiol 298: R1089-R1097, 2010.
31. Crowley SD, Song YS, Sprung G, Griffiths R, Sparks M, Yan M, Burchette JL, Howell DN, Lin EE, Okeiyi B, Stegbauer J, Yang Y, Tharaux PL, and Ruiz P. A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension. Hypertension 55: 99-108, 2010.
32. Dale DC, Boxer L, and Liles WC. The phagocytes: neutrophils and monocytes. Blood 112: 935-945, 2008.
33. Davisson RL. Physiological genomic analysis of the brain renin-Angiotensin system. Am J Physiol Regul Integr Comp Physiol 285: R498-R511, 2003.
34. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, and Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colonystimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol 25: 2106-2113, 2005.
35. De Keulenaer GW, Alexander RW, Ushio-Fukai M, Ishizaka N, and Griendling KK. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J 329 (Pt 3): 653-657, 1998.
36. De Miguel C, Guo C, Lund H, Feng D, and Mattson DL. Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease. Am J Physiol Renal Physiol 300: F734-F742, 2011.
37. de Wardener HE. The hypothalamus and hypertension. Physiol Rev 81: 1599-1658, 2001.
38. Dechend R, Muller DN, Wallukat G, Homuth V, Krause M, Dudenhausen J, and Luft FC. AT1 receptor agonistic antibodies, hypertension, and preeclampsia. Semin Nephrol 24: 571-579, 2004.
39. Dechend R, Viedt C, Muller DN, Ugele B, Brandes RP, Wallukat G, Park JK, Janke J, Barta P, Theuer J, Fiebeler A, Homuth V, Dietz R, Haller H, Kreuzer J, and Luft FC. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 107: 1632-1639, 2003.
40. Devadas S, Zaritskaya L, Rhee SG, Oberley L, and Williams MS. Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation. J ExpMed 195: 59-70, 2002.
41. Dhawan S, Singh S, and Aggarwal BB. Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B. Eur J Immunol 27: 2172-2179, 1997.
42. Ebrahimian T, Li MW, Lemarie CA, Simeone SM, Pagano PJ, Gaestel M, Paradis P, Wassmann S, and Schiffrin EL. Mitogen-Activated protein kinase-Activated protein kinase 2 in angiotensin II-induced inflammation and hypertension: regulation of oxidative stress. Hypertension 57: 245-254, 2011.
43. Elks CM, Mariappan N, Haque M, Guggilam A, Majid DS, and Francis J. Chronic NF-{kappa}B blockade reduces cytosolic and mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR. Am J Physiol Renal Physiol 296: F298-F305, 2009.
44. Elmarakby AA, Quigley JE, Imig JD, Pollock JS, and Pollock DM. TNF-Alpha inhibition reduces renal injury in DOCA-salt hypertensive rats. Am J Physiol Regul Integr Comp Physiol 294: R76-R83, 2008.
45. Elmarakby AA, Quigley JE, Olearczyk JJ, Sridhar A, Cook AK, Inscho EW, Pollock DM, and Imig JD. Chemokine receptor 2b inhibition provides renal protection in angiotensin II salt hypertension. Hypertension 50: 1069-1076, 2007.
46. Elmarakby AA, Quigley JE, Pollock DM, and Imig JD. Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension 47: 557-562, 2006.
47. Fiore MC, Jimenez PM, Cremonezzi D, Juncos LI, and Garcia NH. Statins reverse renal inflammation and endothelial dysfunction induced by chronic high salt intake. Am J Physiol Renal Physiol 301: F263-F270, 2011.
48. Fritz G, Grosch S, Tomicic M, and Kaina B. APE/Ref-1 and the mammalian response to genotoxic stress. Toxicology 193: 67-78, 2003.
49. Gandley RE, Rohland J, Zhou Y, Shibata E, Harger GF, Rajakumar A, Kagan VE, Markovic N, and Hubel CA. Increased myeloperoxidase in the placenta and circulation of women with preeclampsia. Hypertension 52: 387-393, 2008.
50. Goldblatt H. Studies on Experimental Hypertension: Vii. The production of the malignant phase of hypertension. J Exp Med 67: 809-826, 1938.
51. Goligorsky MS and Noiri E. Duality of nitric oxide in acute renal injury. Semin Nephrol 19: 263-271, 1999.
52. Granger DN, Benoit JN, Suzuki M, and Grisham MB. Leukocyte adherence to venular endothelium during ischemia-reperfusion. Am J Physiol 257: G683-G688, 1989.
53. Granger DN, Vowinkel T, and Petnehazy T. Modulation of the inflammatory response in cardiovascular disease. Hypertension 43: 924-931, 2004.
54. Gratze P, Dechend R, Stocker C, Park JK, Feldt S, Shagdarsuren E, Wellner M, Gueler F, Rong S, Gross V, Obst M, Plehm R, Alenina N, Zenclussen A, Titze J, Small K, Yokota Y, Zenke M, Luft FC, and Muller DN. Novel role for inhibitor of differentiation 2 in the genesis of angiotensin IIinduced hypertension. Circulation 117: 2645-2656, 2008.
55. Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS, Astruc B, Mayer JP, Brage S, See TC, Lomas DJ, O?Rahilly S, and Farooqi IS. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 360: 44-52, 2009.
56. Guan Y, Zhang Y, Breyer RM, Fowler B, Davis L, Hebert RL, and Breyer MD. Prostaglandin E2 inhibits renal collecting duct Na + absorption by activating the EP1 receptor. J Clin Invest 102: 194-201, 1998.
57. Guggilam A, Haque M, Kerut EK, McIlwain E, Lucchesi P, Seghal I, and Francis J. TNF-Alpha blockade decreases oxidative stress in the paraventricular nucleus and attenuates sympathoexcitation in heart failure rats. Am J Physiol Heart Circ Physiol 293: H599-H609, 2007.
58. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, and Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204: 2449-2460, 2007.
59. Hazan-Halevy I, Levy T, Wolak T, Lubarsky I, Levy R, and Paran E. Stimulation of NADPH oxidase by angiotensin II in human neutrophils is mediated by ERK, p38 MAPkinase and cytosolic phospholipase A2. J Hypertens 23: 1183-1190, 2005.
60. Hehner SP, Breitkreutz R, Shubinsky G, Unsoeld H, Schulze-Osthoff K, Schmitz ML, and Droge W. Enhancement of T cell receptor signaling by a mild oxidative shift in the intracellular thiol pool. J Immunol 165: 4319-4328, 2000.
61. Henkart PA and Catalfamo M. CD8+ effector cells. Adv Immunol 83: 233-252, 2004.
62. Henke N, Schmidt-Ullrich R, Dechend R, Park J-K, Qadri F, Wellner M, Obst M, Gross V, Dietz R, Luft FC, Scheidereit C, and Muller DN. Vascular endothelial cell specific NF-{kappa}B suppression attenuates hypertension-induced renal damage. Circ Res 101: 268-276, 2007.
63. Herrera J, Ferrebuz A, Macgregor EG, and Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 17: S218-S225, 2006.
64. Hill TW and Moncada S. The renal haemodynamic and excretory actions of prostacyclin and 6-oxo-PGF1 alpha in anaesthetized dogs. Prostaglandins 17: 87-98, 1979.
65. Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, Weyand C, and Harrison DG. Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol 296: R208-R216, 2009.
66. Hoffmann DS, Weydert CJ, Lazartigues E, Kutschke WJ, Kienzle MF, Leach JE, Sharma JA, Sharma RV, and Davisson RL. Chronic tempol prevents hypertension, proteinuria, and poor feto-placental outcomes in BPH/5 mouse model of preeclampsia. Hypertension 51: 1058-1065, 2008.
67. Hwang J, Saha A, Boo YC, Sorescu GP, McNally JS, Holland SM, Dikalov S, Giddens DP, Griendling KK, Harrison DG, and Jo H. Oscillatory shear stress stimulates endothelial production of O2-from p47phox-dependent NAD(P)H oxidases, leading to monocyte adhesion. J Biol Chem 278: 47291-47298, 2003.
68. Ialenti A, Moncada S, and Di Rosa M. Modulation of adjuvant arthritis by endogenous nitric oxide. Br J Pharmacol 110: 701-706, 1993.
69. Imhoff BR and Hansen JM. Extracellular redox status regulates Nrf2 activation through mitochondrial reactive oxygen species. Biochem J 424: 491-500, 2009.
70. Ishibashi M, Hiasa K-i, Zhao Q, Inoue S, Ohtani K, Kitamoto S, Tsuchihashi M, Sugaya T, Charo IF, Kura S, Tsuzuki T, Ishibashi T, Takeshita A, and Egashira K. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res 94: 1203-1210, 2004.
71. Jackson SH, Devadas S, Kwon J, Pinto LA, and Williams MS. T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation. Nat Immunol 5: 818-827, 2004.
72. Jadhav A, Torlakovic E, and Ndisang JF. Hemin therapy attenuates kidney injury in deoxycorticosterone acetate-salt hypertensive rats. Am J Physiol Renal Physiol 296: F521-F534, 2009.
73. Jin ZG, Melaragno MG, Liao DF, Yan C, Haendeler J, Suh YA, Lambeth JD, and Berk BC. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res 87: 789-796, 2000.
74. Johnson RJ, Gordon KL, Giachelli C, Kurth T, Skelton MM, and Cowley AW, Jr. Tubulointerstitial injury and loss of nitric oxide synthases parallel the development of hypertension in the Dahl-SS rat. J Hypertens 18: 1497-1505, 2000.
75. Johnson RJ, Gordon KL, Suga S, Duijvestijn AM, Griffin K, and Bidani A. Renal injury and salt-sensitive hypertension after exposure to catecholamines. Hypertension 34: 151-159, 1999.
76. Jones LB, McGrogan P, Flood TJ, Gennery AR, Morton L, Thrasher A, Goldblatt D, Parker L, and Cant AJ. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patientbased registry. Clin Exp Immunol 152: 211-218, 2008.
77. Kang YM, Ma Y, Zheng JP, Elks C, Sriramula S, Yang ZM, and Francis J. Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin IIinduced hypertension. Cardiovasc Res 82: 503-512, 2009.
78. Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, Neves MF, Laurant P, Paradis P, and Schiffrin EL. T regulatory lymphocytes prevent aldosteroneinduced vascular injury. Hypertension 59: 324-330, 2012.
79. Khromykh LM, Kulikova NL, Anfalova TV, Muranova TA, Abramov VM, Vasiliev AM, Khlebnikov VS, and Kazansky DB. Cyclophilin A produced by thymocytes regulates the migration of murine bone marrow cells. Cell Immunol 249: 46-53, 2007.
80. Kim F, Gallis B, and Corson MA. TNF-Alpha inhibits flow and insulin signaling leading to NO production in aortic endothelial cells. Am J Physiol Cell Physiol 280: C1057-C1065, 2001.
81. Ko EA, Amiri F, Pandey NR, Javeshghani D, Leibovitz E, Touyz RM, and Schiffrin EL. Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-CSF-deficient mice. Am J Physiol Heart Circ Physiol 292: H1789-H1795, 2007.
82. Krotz F, Keller M, Derflinger S, Schmid H, Gloe T, Bassermann F, Duyster J, Cohen CD, Schuhmann C, Klauss V, Pohl U, Stempfle H-U, and Sohn H-Y. Mycophenolate acid inhibits endothelial NAD(P)H oxidase activity and superoxide formation by a rac1-dependent mechanism. Hypertension 49: 201-208, 2007.
83. Kuo JJ, da Silva AA, Tallam LS, and Hall JE. Role of adrenergic activity in pressor responses to chronic melanocortin receptor activation. Hypertension 43: 370-375, 2004.
84. Kvakan H, Dahlman A, Machnik A, van Rooijen N, Qadri F, Dechend R, Titze J, Luft FC, and Muller DN. Macrophage depletion accelerates angiotensin II-induced target organ damage. Hypertension 52: e45, 2008.
85. Kvakan H, Kleinewietfeld M, Qadri F, Park JK, Fischer R, Schwarz I, Rahn HP, Plehm R, Wellner M, Elitok S, Gratze P, Dechend R, Luft FC, and Muller DN. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 119: 2904-2912, 2009.
86. Lara LS, McCormack M, Semprum-Prieto LC, Shenouda S, Majid DS, Kobori H, Navar LG, and Prieto MC. AT1 receptor-mediated augmentation of angiotensinogen, oxidative stress, and inflammation in ANG II-salt hypertension. Am J Physiol Renal Physiol 302: F85-F94, 2012.
87. Lee DL, Sturgis LC, Labazi H, Osborne JB, Jr., Fleming C, Pollock JS, Manhiani M, Imig JD, and Brands MW. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol 290: H935-H940, 2006.
88. Leopold JA, Cap A, Scribner AW, Stanton RC, and Loscalzo J. Glucose-6-phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide bioavailability. FASEB J 15: 1771-1773, 2001.
89. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, and Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 13: 189-197, 2007.
90. Li H, Gao Y, Qi Y, Katovich MJ, Jiang N, Braseth LN, Scheuer DA, Shi P, and Sumners C. Macrophage migration inhibitory factor in hypothalamic paraventricular nucleus neurons decreases blood pressure in spontaneously hypertensive rats. FASEB J 22: 3175-3185, 2008.
91. Li K, Guo D, Zhu H, Hering-Smith KS, Hamm LL, Ouyang J, and Dong Y. Interleukin-6 stimulates epithelial sodium channels in mouse cortical collecting duct cells. Am J Physiol Regul Integr Comp Physiol 299: R590-R595, 2010.
92. Liao DF, Jin ZG, Baas AS, Daum G, Gygi SP, Aebersold R, and Berk BC. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem 275: 189-196, 2000.
93. Liao TD, Yang XP, Liu YH, Shesely EG, Cavasin MA, Kuziel WA, Pagano PJ, and Carretero OA. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension 52: 256-263, 2008.
94. Liew CC and Gornall AG. Effects of aldosterone on blood pressure and glucose-6-phosphate dehydrogenase activity of heart muscle. Can J Physiol Pharmacol 47: 193-197, 1969.
95. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, and Weyrich AS. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 154: 485-490, 2001.
96. Liu H, Colavitti R, Rovira II, and Finkel T. Redox-dependent transcriptional regulation. Circ Res 97: 967-974, 2005.
97. Liu J, Yang F, Yang XP, Jankowski M, and Pagano PJ. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol 23: 776-782, 2003.
98. Lob HE, Marvar PJ, Guzik TJ, Sharma S, McCann LA, Weyand C, Gordon FJ, and Harrison DG. Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension 55: 277-283, 276p following 283, 2010.
99. Lu Y, Chen J, Yin X, and Zhao H. Angiotensin II receptor 1 involved in the central pressor response induced by interleukin-1 beta in the paraventricular nucleus. Neurol Res 31: 420-424, 2009.
100. Luther JM, Gainer JV, Murphey LJ, Yu C, Vaughan DE, Morrow JD, and Brown NJ. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 48: 1050-1057, 2006.
101. Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, Park J-K, Beck F-X, Muller DN, Derer W, Goss J, Ziomber A, Dietsch P, Wagner H, van Rooijen N, Kurtz A, Hilgers KF, Alitalo K, Eckardt K-U, Luft FC, Kerjaschki D, and Titze J. Macrophages regulate saltdependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med 15: 545-552, 2009.
102. Maki-Petaja KM, Hall FC, Booth AD, Wallace SM, Yasmin, Bearcroft PW, Harish S, Furlong A, McEniery CM, Brown J, and Wilkinson IB. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-Alpha therapy. Circulation 114: 1185-1192, 2006.
103. Markewitz BA, Michael JR, and Kohan DE. Cytokineinduced expression of a nitric oxide synthase in rat renal tubule cells. J Clin Invest 91: 2138-2143, 1993.
104. Martinvalet D, Zhu P, and Lieberman J. Granzyme A induces caspase-independent mitochondrial damage, a required first step for apoptosis. Immunity 22: 355-370, 2005.
105. Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, Rossi P, Gattorno M, Rabusin M, Azzari C, Dellepiane RM, Pietrogrande MC, Trizzino A, Di Bartolomeo P, Martino S, Carpino L, Cossu F, Locatelli F, Maccario R, Pierani P, Putti MC, Stabile A, Notarangelo LD, Ugazio AG, Plebani A, and De Mattia D. Clinical features, longterm follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol 126: 155-164, 2008.
106. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, and Medford RM. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 92: 1866-1874, 1993.
107. Marvar PJ, Lob H, Vinh A, Zarreen F, and Harrison DG. The central nervous system and inflammation in hypertension. Curr Opin Pharmacol 11: 156-161, 2011.
108. Mathis KW, Venegas-Pont M, Masterson CW, Stewart NJ, Wasson KL, and Ryan MJ. Oxidative stress promotes hypertension and albuminuria during the autoimmune disease systemic lupus erythematosus. Hypertension 59: 673-679, 2012.
109. McCord N, Ayuk P, McMahon M, Boyd RC, Sargent I, and Redman C. System y + arginine transport and NO production in peripheral blood mononuclear cells in pregnancy and preeclampsia. Hypertension 47: 109-115, 2006.
110. McNally JS, Davis ME, Giddens DP, Saha A, Hwang J, Dikalov S, Jo H, and Harrison DG. Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol Heart Circ Physiol 285: H2290-H2297, 2003.
111. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, and Janeway CA, Jr. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 2: 253-258, 1998.
112. Meier B, Radeke HH, Selle S, Younes M, Sies H, Resch K, and Habermehl GG. Human fibroblasts release reactive oxygen species in response to interleukin-1 or tumour necrosis factor-Alpha. Biochem J 263: 539-545, 1989.
113. Mervaala EM, Muller DN, Park JK, Schmidt F, Lohn M, Breu V, Dragun D, Ganten D, Haller H, and Luft FC. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 33: 389-395, 1999.
114. Mezzano S, Droguett A, Burgos ME, Ardiles LG, Flores CA, Aros CA, Caorsi I, Vio CP, Ruiz-Ortega M, and Egido J. Renin-Angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl S64-S70, 2003.
115. Minagawa M, Narita J, Tada T, Maruyama S, Shimizu T, Bannai M, Oya H, Hatakeyama K, and Abo T. Mechanisms underlying immunologic states during pregnancy: possible association of the sympathetic nervous system. Cell Immunol 196: 1-13, 1999.
116. Mir M, Asensio VJ, Tolosa L, Gou-Fabregas M, Soler RM, Llado J, and Olmos G. Tumor necrosis factor alpha and interferon gamma cooperatively induce oxidative stress and motoneuron death in rat spinal cord embryonic explants. Neuroscience 162: 959-971, 2009.
117. Mohan S, Koyoma K, Thangasamy A, Nakano H, Glickman RD, and Mohan N. Low shear stress preferentially enhances IKK activity through selective sources of ROS for persistent activation of NF-kappaB in endothelial cells. Am J Physiol Cell Physiol 292: C362-C371, 2007.
118. Mohan S, Mohan N, and Sprague EA. Differential activation of NF-kappa B in human aortic endothelial cells conditioned to specific flow environments. Am J Physiol 273: C572-C578, 1997.
119. Mohazzab KM, Kaminski PM, and Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 266: H2568-H2572, 1994.
120. Moncada S. The 1991 Ulf von Euler Lecture. The L-Arginine: nitric oxide pathway. Acta Physiol Scand 145: 201-227, 1992.
121. Moncada S and Higgs A. The L-Arginine-nitric oxide pathway. N Engl J Med 329: 2002-2012, 1993.
122. Moriuchi H, Moriuchi M, and Fauci AS. Nuclear factorkappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J Immunol 158: 3483-3491, 1997.
123. Mosser DM and Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969, 2008.
124. Muller DN, Dechend R, Mervaala EMA, Park J-K, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, and Luft FC. NF-{kappa}B inhibition ameliorates angiotensin IIinduced inflammatory damage in rats. Hypertension 35: 193-201, 2000.
125. Muller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, Kreuzer J, Heidecke H, Haller H, Zenke M, and Luft FC. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 161: 1679-1693, 2002.
126. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, and Namba M. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-Alpha and angiotensin II. Circulation 98: 794-799, 1998.
127. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, Ruiz P, Smithies O, and Coffman TM. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 104: 1693-1701, 1999.
128. Ni W, Zhan Y, He H, Maynard E, Balschi JA, and Oettgen P. Ets-1 is a critical transcriptional regulator of reactive oxygen species and p47phox gene expression in response to angiotensin II. Circ Res 101: 985-994, 2007.
129. Niskanen L, Laaksonen DE, Nyyssonen K, Punnonen K, Valkonen VP, Fuentes R, Tuomainen TP, Salonen R, and Salonen JT. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 44: 859-865, 2004.
130. Okuda T and Grollman A. Passive transfer of autoimmune induced hypertension in the rat by lymph node cells. Tex Rep Biol Med 25: 257-264, 1967.
131. Parker DC. T cell-dependent B cell activation. Annu Rev Immunol 11: 331-360, 1993.
132. Parra G, Quiroz Y, Salazar J, Bravo Y, Pons H, Chavez M, Johnson RJ, and Rodriguez-Iturbe B. Experimental induction of salt-sensitive hypertension is associated with lymphocyte proliferative response to HSP70. Kidney Int Suppl S55-S59, 2008.
133. Pauletto P and Rattazzi M. Inflammation and hypertension: the search for a link. Nephrol Dial Transplant 21: 850-853, 2006.
134. Petros A, Bennett D, and Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 338: 1557-1558, 1991.
135. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999.
136. Polichnowski AJ, Lu L, and Cowley AW. Renal injury in angiotensin II + l-NAME-induced hypertensive rats is independent of elevated blood pressure. Am J Physiol Renal Physiol 300: F1008-F1016, 2011.
137. Purkayastha S, Zhang G, and Cai D. Uncoupling the mechanisms of obesity and hypertension by targeting hypothalamic IKK-beta and NF-kappaB. Nat Med 17: 883-887, 2011.
138. Quintero M, Colombo SL, Godfrey A, and Moncada S. Mitochondria as signaling organelles in the vascular endothelium. Proc Natl Acad Sci U S A 103: 5379-5384, 2006.
139. Quiroz Y, Pons H, Gordon KL, Rincon J, Chavez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, Johnson RJ, and Rodriguez-Iturbe B. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol 281: F38-F47, 2001.
140. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, and Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97: 1916-1923, 1996.
141. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, and Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 98: 2572-2579, 1996.
142. Ramseyer VD, Hong NJ, and Garvin JL. Tumor necrosis factor alpha decreases nitric oxide synthase type 3 expression primarily via Rho/Rho kinase in the thick ascending limb. Hypertension 59: 1145-1150, 2012.
143. Rocha R and Stier CT, Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 12: 308-314, 2001.
144. Rodriguez-Iturbe B, Pons H, Quiroz Y, Gordon K, Rincon J, Chavez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, and Johnson RJ. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 59: 2222-2232, 2001.
145. Rodrguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Cha?vez M, Herrera-Acosta J, Johnson RJ, and Pons HA. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 282: F191-F201, 2002.
146. Rodriguez-Iturbe B, Zhan CD, Quiroz Y, Sindhu RK, and Vaziri ND. Antioxidant-rich diet relieves hypertension and reduces renal immune infiltration in spontaneously hypertensive rats. Hypertension 41: 341-346, 2003.
147. Roos D, de Boer M, Kuribayashi F, Meischl C, Weening RS, Segal AW, Ahlin A, Nemet K, Hossle JP, Bernatowska-Matuszkiewicz E, and Middleton-Price H. Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Blood 87: 1663-1681, 1996.
148. Roson MI, Della Penna SL, Cao G, Gorzalczany S, Pandolfo M, Toblli JE,
149. Ryan MJ and McLemore GR, Jr. Hypertension and impaired vascular function in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 292: R736-R742, 2007.
150. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, and Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A 90: 7240-7244, 1993.
151. Salvemini D, Seibert K, Masferrer JL, Misko TP, Currie MG, and Needleman P. Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest 93: 1940-1947, 1994.
152. Sato K, Niessner A, Kopecky SL, Frye RL, Goronzy JJ, and Weyand CM. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med 203: 239-250, 2006.
153. Satoh K, Nigro P, Matoba T, O?Dell MR, Cui Z, Shi X, Mohan A, Yan C, Abe J-i, Illig KA, and Berk BC. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med 15: 649-656, 2009.
154. Schro?der K, Zhang M, Benkhoff S, Mieth A, Pliquett R, Kosowski J, Kruse C, Luedike P, Michaelis UR, Weissmann N, Dimmeler S, Shah AM, and Brandes RP. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res 110: 1217-1225, 2012.
155. Segal BH, Leto TL, Gallin JI, Malech HL, and Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 79: 170-200, 2000.
156. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, and Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 290: 2945-2951, 2003.
157. Shahid M, Francis J, and Majid DSA. Tumor necrosis factor-{alpha} induces renal vasoconstriction as well as natriuresis in mice. Am J Physiol Renal Physiol 295: F1836-F1844, 2008.
158. Shahid M, Francis J, Matrougui K, and Majid DSA. Involvement of tumor necrosis factor-{alpha} in natriuretic response to systemic infusion of nitric oxide synthase inhibitor in anesthetized mice. Am J Physiol Renal Physiol 299: F217-F224, 2010.
159. Sharma K, Cook A, Smith M, Valancius C, and Inscho EW. TGF-b impairs renal autoregulation via generation of ROS. Am J Physiol Renal Physiol 288: F1069-F1077, 2005.
160. Shi P, Diez-Freire C, Jun JY, Qi Y, Katovich MJ, Li Q, Sriramula S, Francis J, Sumners C, and Raizada MK. Brain microglial cytokines in neurogenic hypertension. Hypertension 56: 297-303, 2010.
161. Silva MT. When two is better than one: macrophages and neutrophils work in concert in innate immunity as complementary and cooperative partners of a myeloid phagocyte system. J Leukoc Biol 87: 93-106, 2010.
162. Sima AV, Stancu CS, and Simionescu M. Vascular endothelium in atherosclerosis. Cell Tissue Res 335: 191-203, 2009.
163. Sriramula S, Cardinale JP, Lazartigues E, and Francis J. ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension. Cardiovasc Res 92: 401-408, 2011.
164. Sriramula S, Haque M, Majid DSA, and Francis J. Involvement of tumor necrosis factor-{alpha} in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension 51: 1345-1351, 2008.
165. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, and Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 92: 3893-3897, 1995.
166. Stoos BA, Garcia NH, and Garvin JL. Nitric oxide inhibits sodium reabsorption in the isolated perfused cortical collecting duct. J Am Soc Nephrol 6: 89-94, 1995.
167. Stumpf C, John S, Jukic J, Yilmaz A, Raaz D, Schmieder RE, Daniel WG, and Garlichs CD. Enhanced levels of platelet Pselectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens 23: 995-1000, 2005.
168. Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K, and Nagata S. Expression of the Fas ligand in cells of T cell lineage. J Immunol 154: 3806-3813, 1995.
169. Sun C, Li H, Gao Y, Matsuura T, Upchurch PA, Raizada MK, and Sumners C. Lack of macrophage migration inhibitory factor regulation is linked to the increased chronotropic action of angiotensin II in SHR neurons. Hypertension 49: 528-534, 2007.
170. Suzuki J, Jin ZG, Meoli DF, Matoba T, and Berk BC. Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res 98: 811-817, 2006.
171. Svendsen UG. Evidence for an initial, thymus independent and a chronic, thymus dependent phase of DOCA and salt hypertension in mice. Acta Pathol Microbiol Scand A 84: 523-528, 1976.
172. Svendsen UG. Spontaneous hypertension and hypertensive vascular disease in the NZB strain of mice. Acta Pathol Microbiol Scand A 85: 548-554, 1977.
173. Tang PCY, Qin L, Zielonka J, Zhou J, Matte-Martone C, Bergaya S, van Rooijen N, Shlomchik WD, Min W, Sessa WC, Pober JS, and Tellides G. MyD88-dependent, superoxide-initiated inflammation is necessary for flowmediated inward remodeling of conduit arteries. J Exp Med 205: 3159-3171, 2008.
174. Tatsukawa Y, Hsu WL, Yamada M, Cologne JB, Suzuki G, Yamamoto H, Yamane K, Akahoshi M, Fujiwara S, and Kohno N. White blood cell count, especially neutrophil count, as a predictor of hypertension in a Japanese population. Hypertens Res 31: 1391-1397, 2008.
175. Thabet SR, Wu J, Chen W, Marvar PJ, Gongora MC, Madhur MS, Blinder Y, Weyand C, and Harrison DG. The role of CD8 + T cells, IP-10 and MMP12 in hypertension. Hypertension 58: e49 Abstract, 2011.
176. Thannickal VJ and Fanburg BL. Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor beta 1. J Biol Chem 270: 30334-30338, 1995.
177. Thway TM, Shlykov SG, Day MC, Sanborn BM, Gilstrap LC, 3rd, Xia Y, and Kellems RE. Antibodies from preeclamptic patients stimulate increased intracellular Ca2 + mobilization through angiotensin receptor activation. Circulation 110: 1612-1619, 2004.
178. Tian N, Gu JW, Jordan S, Rose RA, Hughson MD, and Manning RD, Jr. Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol 292: H1018-H1025, 2007.
179. Tian N, Moore RS, Braddy S, Rose RA, Gu JW, Hughson MD, and Manning RD, Jr. Interactions between oxidative stress and inflammation in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol 293: H3388-H3395, 2007.
180. Ungvari Z, Wolin MS, and Csiszar A. Mechanosensitive production of reactive oxygen species in endothelial and smooth muscle cells: role in microvascular remodeling? Antioxid Redox Signal 8: 1121-1129, 2006.
181. van der Veen RC, Dietlin TA, Karapetian A, Holland SM, and Hofman FM. Extra-cellular superoxide promotes T cell expansion through inactivation of nitric oxide. J Neuroimmunol 153: 183-189, 2004.
182. Vecchione C, Patrucco E, Marino G, Barberis L, Poulet R, Aretini A, Maffei A, Gentile MT, Storto M, Azzolino O, Brancaccio M, Colussi GL, Bettarini U, Altruda F, Silengo L, Tarone G, Wymann MP, Hirsch E, and Lembo G. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma. J Exp Med 201: 1217-1228, 2005.
183. Venegas-Pont M, Manigrasso MB, Grifoni SC, LaMarca BB, Maric C, Racusen LC, Glover PH, Jones AV, Drummond HA, and Ryan MJ. Tumor necrosis factor-Alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus. Hypertension 56: 643-649, 2010.
184. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, and Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106: 1439-1441, 2002.
185. Verlohren S, Muller DN, Luft FC, and Dechend R. Immunology in hypertension, preeclampsia, and target-organ damage. Hypertension 54: 439-443, 2009.
186. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, and Mickle DA. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105: 1890-1896, 2002.
187. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, and Stewart DJ. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106: 913-919, 2002.
188. Vital SA, Terao S, Nagai M, and Granger DN. Mechanisms underlying the cerebral microvascular responses to angiotensin II-induced hypertension. Microcirculation 17: 641-649, 2010.
189. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, and Verma S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107: 1783-1790, 2003.
190. Weber C, Erl W, Pietsch A, Strobel M, Ziegler-Heitbrock HW, and Weber PC. Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-kappa B mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals. Arterioscler Thromb 14: 1665-1673, 1994.
191. Wenzel P, Knorr M, Kossmann S, Stratmann J, Hausding M, Schuhmacher S, Karbach SH, Schwenk M, Yogev N, Schulz E, Oelze M, Grabbe S, Jonuleit H, Becker C, Daiber A, Waisman A, and Munzel T. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction/clinical perspective. Circulation 124: 1370-1381, 2011.
192. Wever RM, van Dam T, van Rijn HJ, de Groot F, and Rabelink TJ. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun 237: 340-344, 1997.
193. Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 289: R913-R935, 2005.
194. Xia H, Suda S, Bindom S, Feng Y, Gurley SB, Seth D, Navar LG, and Lazartigues E. ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. PLoS One 6: e22682, 2011.
195. Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, Nakamura Y, Itoh Y, and Kajii E. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol 153: 1183-1190, 2001.
196. Yan G, You B, Chen SP, Liao JK, and Sun J. Tumor necrosis factor-Alpha downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-Alpha 1. Circ Res 103: 591-597, 2008.
197. Yang B and Rizzo V. TNF-Alpha potentiates proteintyrosine nitration through activation of NADPH oxidase and eNOS localized in membrane rafts and caveolae of bovine aortic endothelial cells. Am J Physiol Heart Circ Physiol 292: H954-H962, 2007.
198. Yasunari K, Maeda K, Nakamura M, and Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension 39: 777-780, 2002.
199. Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, and Oettgen P. Ets-1 is a critical regulator of Ang IImediated vascular inflammation and remodeling. J Clin Invest 115: 2508-2516, 2005.
200. Zhang JD, Patel MB, Song YS, Griffiths R, Burchette J, Ruiz P, Sparks MA, Yan M, Howell DN, Gomez JA, Spurney RF, Coffman TM, and Crowley SD. A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ Res 110: 1604-1617, 2012.
201. Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H, Penninger JM, Scholey JW, Kassiri Z, and Oudit GY. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 57: 314-322, 2011.
202. Zimmerman MC, Lazartigues E, Lang JA, Sinnayah P, Ahmad IM, Spitz DR, and Davisson RL. Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res 91: 1038-1045, 2002.